A phase 1, first-in-human, dose-escalation and expansion study of FX-909 in patients with advanced solid malignancies, including advanced urothelial carcinoma.
Gopa Iyer(Memorial Sloan Kettering Cancer Center), Matt D. Galsky(University of California, San Francisco), Michael L. Meyers(Eastern Cooperative Oncology Group), Jennifer Tepper, Benjamin Garmezy(Sarah Cannon), Michaela Bowden(Brigham and Women's Hospital), Drew Rasco(Texas Oncology), Joaquim Bellmunt(Dana-Farber Cancer Institute), Matthew I. Milowsky(UNC Lineberger Comprehensive Cancer Center), Xīn Gào(Qingdao University), Evisa Gjini(Brigham and Women's Hospital), Melissa A. Moles, Ildefonso Ismael Rodriguez Rivera(Texas Oncology)
Cited by 5
Related Papers
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k